Using accelerometers to measure physical activity in cancer patients
APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials. A Feasibility Study Evaluating the Use of Accelerometers to Capture Physical Activity Levels in Cancer Patients on Early Phase Clinical Trials
This study is testing whether wearing a device that tracks movement can help cancer patients understand their activity levels and fatigue during treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | University of Manchester Academic / other |
| Locations | 8 sites (Milan and 7 other locations) |
| Trial ID | NCT06868355 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the feasibility of using wearable accelerometers to collect data on physical activity and sleep patterns in cancer patients enrolled in early phase clinical trials. Over a period of 5-6 weeks, participants will wear the device to provide insights into their activity levels and fatigue, which are critical for managing their treatment and interventions. The study seeks to improve the understanding of how physical activity impacts cancer patient outcomes, particularly in those experiencing treatment-related fatigue.
Who should consider this trial
Good fit: Ideal candidates include cancer patients aged 16 and older who are enrolled in early phase clinical trials and can comply with study procedures.
Not a fit: Patients who are not eligible for early phase clinical trials or those unable to comply with study requirements may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better management of physical activity and fatigue in cancer patients, enhancing their treatment outcomes.
How similar studies have performed: While the use of accelerometers in other populations has shown promise, this specific approach in cancer patients on early phase clinical trials is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Voluntary informed consent. * Aged at least 16 years. * Consented to an early phase clinical trial. * Willingness to wear a device for the duration of the study. * Willingness to comply with scheduled study procedures. * ECOG PS 0 or 1. Exclusion Criteria: * Judgement by the investigator that the individual should not participate if they are unlikely to comply with study procedures and requirements. * Patient deemed ineligible for enrolment onto an early phase clinical trial.
Where this trial is running
Milan and 7 other locations
- National Cancer Institute of Milan (INT) — Milan, Italy (Recruiting)
- Vall d'Hebron Institute of Oncology (VHIO) — Barcelona, Spain (Recruiting)
- START Madrid CIOCC — Madrid, Spain (Not_yet_recruiting)
- START Madrid Fundación Jiménez Díaz (FJD) Quiron Salud Hospital — Madrid, Spain (Not_yet_recruiting)
- Clínica Universidad de Navarra — Pamplona, Spain (Recruiting)
- Instituto de Investigación Sanitaria (INCLIVA) — Valencia, Spain (Recruiting)
- University Hospitals of Leicester NHS Trust — Leicester, United Kingdom (Completed)
- The Christie NHS Foundation Trust — Manchester, United Kingdom (Completed)
Study contacts
- Study coordinator: Gayle Patterson
- Email: gayle.patterson@manchester.ac.uk
- Phone: 07919719013
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.